邓勇，男，博士，教授，博士生导师
单位：四川大学华西药学院药物化学系
通讯地址：成都市人民南路三段十七号四川大学华西药学院
E-mail: dengyongy@sohu.com
2001年7月获四川大学药物化学专业博士学位后留校任教，从事药物化学的教学和科研工作；先后主讲本科生及研究生的《药物化学》、《有机杂环化学》等课程，现主要研究领域为：抗神经退行性疾病药物研究、药物合成工艺及产业化研究。近年来，作为负责人或主研人员承担国家自然科学基金面上项目3项、国家“十二五”重大新药创制项目2项、国家“十一五”重大新药创制项目2项、教育部博士点基金1项、国家“十五”重大科技专项“创新药物与中药现代化”项目1项、四川省重点项目3项、四川大学青年科学基金1项、企业药物开发项目20余项（包括：盐酸沙丙蝶呤、利奈唑胺、利伐沙班、雷美替胺、熊去氧胆酸、牛磺熊去氧胆酸、奥贝胆酸、氟比洛芬、重酒石酸卡巴拉汀、地红霉素、氯雷他啶、盐酸替扎尼定、拉米夫定、曲氟尿苷、奥沙利铂、他唑巴坦、格列美脲等）；在国内外核心期刊上发表研究论文90余篇（SCI收录72篇），获授权发明专利70余件，参编本科生教材3本。被评为四川省学术和技术带头人后备人选、四川省卫生厅学术和技术带头人。现担任国家科技奖励评审人，国家自然科学基金通讯评审人，教育部学位与研究生教育评估工作平台评审人，多个省市科技计划项目评审人，以及多本国际期刊的审稿人（European Journal of Medicinal Chemistry、Bioorganic & Medicinal Chemistry、Bioorganic & Medicinal Chemistry Letters、Bioorganic Chemistry、MedChemComm、Food & Function、ChemMedChem、Journal of Medicinal Chemistry、ACS Medicinal Chemistry Letters、ACS Chemical Neuroscience、Medicinal Research Reviews、Molecular Pharmaceutics、International Journal of Biological Macromolecules等）。
主要研究领域
1、抗神经退行性疾病药物研究
2、药物合成工艺及产业化研究
近年代表性论著
1、6-Benzyloxyphthalides as selective and reversible monoamine oxidase B inhibitors with antioxidant and anti-neuroinflammatory activities for Parkinson’s disease treatment.Bioorg. Chem.2022, 120, 105623.
2、Discovery of novel 3-butyl-6-benzyloxyphthalide Mannich base derivatives as multifunctional agents against Alzheimer’s disease.Bioorg. Med. Chem.2022, 58, 116660.
3、Development of novel 2-aminoalkyl-6-(2-hydroxyphenyl)pyridazin-3(2H)-one derivatives as balanced multifunctional agents against Alzheimer's disease.Eur. J. Med. Chem.2022, 230, 114098.
4、Phthalimide-(N-alkylbenzylamine) cysteamide hybrids as multifunctional agents against Alzheimer’s disease: Design, synthesis, and biological evaluation.Chem. Bio. Drug Des.2021, 98, 493-500.
5、2-(3-Hydroxybenzyl)benzo[d]isothiazol-3(2H)-one Mannich base derivatives as potential multifunctional anti-Alzheimer’s agents.Med. Chem. Res.2021, 30, 1249-1264.
6、Design, synthesis, and in vitro evaluation of 4-aminoalkyl-1(2H)-phthalazinones as potential multifunctional anti-Alzheimer’s disease agents.Bioorg. Chem.2021, 111, 104895.
7、Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer’s disease.Bioorg. Med. Chem.2021, 35, 116074.
8、Design, synthesis and evaluation of novel dimethylamino chalcone-Oalkylamines derivatives as potential multifunctional agents against Alzheimer’s disease.Eur. J. Med. Chem.2021, 216, 113310.
9、Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.Bioorg. Med. Chem.2020, 28, 115400.
10、Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson’s disease.Bioorg. Chem.2020, 97, 103707.
11、Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer’s disease.Bioorg. Med. Chem.2020, 28, 115374.
12、Flurbiprofen-chalcone hybrid mannich base derivatives as balanced multifunctional agents against Alzheimer’s disease: design, synthesis and biological evaluation.Bioorg. Chem.2020, 94, 103477.
13、Discovery of 4-OH-flurbiprofen mannich base derivatives as potential Alzheimer’s disease treatment with multiple inhibitory activities.Bioorg. Med. Chem.2019, 27, 991-1001.
14、Design, synthesis and evaluation of chalcone mannich base derivatives as multifunctional agents for the potential treatment of Alzheimer’s disease.Bioorg. Chem.2019, 87, 395-408.
15、Novel salicylamide derivatives as potent multifunctional agents for the treatment of Alzheimer's disease: design, synthesis and biological evaluation.Bioorg. Chem.2019, 84, 137-149.
16、Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer’s disease.Bioorg. Med. Chem.2018, 26, 6115-6127.
17、Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetyl cholinesterase, monoamine oxidases and beta-amyloid aggregation inhibitory activities as potential agents against Alzheimer’s disease.Bioorg. Med. Chem.2018, 26, 1885-1895.
18、Design, synthesis and evaluation of pterostilbene beta-amino alcohol derivatives as multifunctional agents for Alzheimer’s disease treatment.Bioorg. Chem.2018, 78, 298-306.
19、Design, synthesis and evaluation of 4-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer’s disease treatment.Bioorg. Med. Chem.2018, 26, 1102-1115.
20、Design, synthesis and evaluation of scutellarein-O-acetamidoalkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.2017, 135, 307-323.
21、Pyridoxine-resveratrol hybrids mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer’s disease.Bioorg. Chem.2017,71, 305-314.
22、Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and beta-amyloid aggregation inhibitory activities as potential agents against Alzheimer’s disease.Bioorg. Med. Chem.2017, 25, 1997-2009.
23、Aurone mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggregation and neuroprotective properties for the treatment of Alzheimer's disease.Eur. J. Med. Chem.2017, 126, 762-775.
24、DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-beta aggregation and monoamine oxidases with high antioxidant potency for Alzheimer’s therapy.Bioorg. Med. Chem. Lett.2017, 27, 718-722.
25、Multi-target drug design strategy against Alzheimer’s disease: homoisoflavonoid mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.Bioorg. Med. Chem.2017, 25, 714-726.
26、Design, synthesis and biological evaluation of 4-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's diseas.Bioorg. Med. Chem.2017, 25, 1030-1041.
27、Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer’s disease.Bioorg. Med. Chem.2016, 24, 2342-2351.
28、Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-beta-amyloid aggregation and antioxidant properties for the treatment of Alzheimer’s disease.Bioorg. Med. Chem. Lett.2016, 26, 2035-2039.
29、Design, synthesis, and biological evaluation of scutellarein carbamate derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.Chem. Bio. Drug Des.2015, 86, 1168-1177.
30、Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer's disease.Eur. J. Med. Chem.2015, 94, 348-366.
31、Design, synthesis and evaluation of chromone-2-carboxamido-alkylbenzylamines as multifunctional agents for the treatment of Alzheimer’s disease.Bioorg. Med. Chem.2015, 23, 911-923.
32、Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer’s disease.Bioorg. Med. Chem.2015, 23, 668-680.
33、Synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.2014, 76, 314-331.
34、Therapeutic efficacy of a novel non-peptide alph v beta 3 integrin antagonist for pathological retinal angiogenesis in mice.Exp. Eye Res.2014, 129, 119-126.
35、Synthesis and biological evaluation of novel naphthalene compounds as potential antidepressant agents.Eur. J. Med. Chem.2014, 82, 263-273.
36、Synthesis of pterostilbene and resveratrol carbamate derivatives as potential dual cholinesterase inhibitors and neuroprotective agents.Res. Chem. Intermed.2014, 40, 787-800.
代表性发明专利
1、一类黄酮烷基胺类化合物其制备方法和用途. WO 2014111004 A1.
2、一类金雀异黄酮烷基胺类化合物其制备方法和用途. WO 2014111028 A1.
3、五碳或六碳单糖-(E)-3-(呋喃-2-基)丙烯酸单酯类化合物及其制备方法和用途. WO 2012055146 A1.
4、1,3-噁唑烷-2-酮类化合物其制备方法和用途. WO 2012171248 A1.
5、非甾体雄激素受体调节剂及其制备方法、药物组合物和用途. WO 2006125397 A1.
